Project Grant F31AI202991
Award Date 2/17/27
Completion Date 8/31/28
Dollars Obligated $100K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Rhode Island Hospital $195,475 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance understanding of the physiological mechanisms by which infections contribute to stunting and wasting in young children and to support career development of the principal investigator. The research leverages well-characterized samples and clinical data from a completed NIH-funded randomized,...
- The National Institute of Allergy and Infectious Diseases awarded Brown University $791,611 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and develop novel antimalarial drugs targeting PFGARP as a parenteral therapy for severe falciparum malaria. The project conducts a targeted high-throughput drug screen to identify compounds that mimic the lethal activity of antibodies recognizing PFGARP, optimizes and down-selects lead candidates,...
- The National Institute of Allergy and Infectious Diseases awarded Brown University $100,228 on February 13, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess climate and spatial drivers of influenza dynamics across temperate and tropical settings. The recipient will develop a multinational dataset integrating spatially- and temporally-resolved influenza surveillance data, environmental variables, and human mobility indicators to evaluate how weather factors...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $159,140 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular epidemiology research on New Delhi metallo-B-lactamase-producing Enterobacterales (NDM-E) infections. The research integrates genotype, phenotype, and patient-level outcomes to develop allele-specific therapeutic guidance for NDM-E treatment. Aim 1 defines the genetic epidemiology of...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- The National Institute of Allergy and Infectious Diseases (NIAID), within the Department of Health and Human Services National Institutes of Health, awarded $515,625 to The Salk Institute for Biological Studies on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI197945). The award funds research into molecular pathways leading to drug resistance in HIV-1 integrase. The project investigates how and why distinct...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $434,500 on August 1, 2026, under CFDA 93.855 (Allergy and Infectious Diseases Research) to conduct genomic and serological research distinguishing imported from locally transmitted malaria in the Ethiopian highlands. The recipient will sequence over 1,000 Plasmodium falciparum and over 800 P. vivax samples collected since 2019 to assess whether imported infections spread in the highlands, whether...
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $148,614 on March 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support interdisciplinary training and research experience in vector-borne disease epidemiology, migration, and environmental health. The award funds a fellowship supporting mentored training in the assessment of malaria transmission dynamics near migrant communities in Panama's Darien and Guna Yala regions....
- The National Institute of Allergy and Infectious Diseases awarded Rhode Island Hospital $2.737 million on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a randomized controlled trial evaluating praziquantel treatment frequencies for schistosomiasis-related hepatic fibrosis in Uganda. Rhode Island Hospital will enroll 600 subjects aged 15–40 with compensated schistosomal fibrosis at Lake Albert, Uganda, and randomize them to receive...